CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment
GALWAY, Ireland , April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026,...
Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion,...
GALWAY, Ireland , March 27, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth...
Spin-offs are a way for CEOs to unleash growth and unlock shareholder value; this is a look at five spin-offs that are getting bullish attention from analysts.
Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area
/Insulet%20Corporation%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
Insulet has underperformed the Dow recently, yet analysts remain highly optimistic about the stock’s prospects.
/Zimmer%20Biomet%20Holdings%20Inc%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
Zimmer Biomet Holdings stock has lagged other medical device stocks over the past year, while analysts are neutral about its prospects.
$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’...
Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'